Institut National De La Sante Et De La Recherche Medicale

Université D'angers

Other

Centre National De La Recherche Scientifique

Laboratoires Des Produits Ethiques Ethypharm

Centre Hospitalier Universitaire D'angers

Ethypharm Sa

L'universite D'angers

Laboratoires Des Prodiuts Ethiques Ethypharm

Mainelab

Universite D'angers France

Centre Hospitalier Universitaire D'angers Cedex France

Inserm

Jean-Pierre Benoit

Patrick Saulnier

Nicolas Anton

Philippe Menei

Joël Richard

Olivier Thomas

Nathalie Faisant

Marie-Claire Venier

Elisabeth Bac

Jo&euml;l Richard

Claudia Montero-Menei

Valérie Tatard

Alyaa Adel Ramadan

Claire Dulieu

Albert Lisbona

St&eacute;phane Martin

Frédéric Tewes

Benoit Denizot

Sophie Morteau

Frank Boury

Béatrice Heurtault

Manuel Bardies

Jacques-Emile Proust

Guillaume Bastiat

Brigitte Pech

Jérôme Bejaud

Marion Pitorre

Alexandra Paillard

Thomas Perrier

Marie Brachet-Botineau

Giovanna Lollo

Marie Brachet - Botineau

Maire-Claire Venier

The present invention concerns modified nucleobases, nucleosides, deoxynucleosides, and/or their derivatives, nanocapsules comprising them, hydrogels and oleogels comprising said nanocapsules or said above-mentioned compounds and their uses, in particular their pharmaceutical uses.

Nanocapsules comprising modified nucleobases and/or nucleosides, hydrogels and oleogels comprising them and uses thereof

The treatment of cancer using platinum-based compounds includes certain drawbacks such as biocompatibility, loading efficacy, leakage of drugs during storage and in the bloodstream, more particularly due to the nature of the nanocarriers for platinum delivery. A nanosystem that allows improving platinum-based drug in vivo performance, kinetics and efficacy. In particular, nanoparticles useful as drug delivery system, these nanoparticles being formed from at least: (a) platinum-based drug, (b) poly-L-arginine, and (c) hyaluronic acid. Particularly, these nanoparticles have been tested in terms of entrapment efficiency and also carried out in vitro experiments in 2D cell culture (viability studies on B6KPC3, A549 and HT-29 cells) and 3D cell model (spheroids made of HTC-116) and in vivo experiments (by injecting intravenously to mice the nanoparticles or comparative oxaliplatin solution) to prove their efficiency.

Drug delivery system

The present invention relates to a method for preparing poloxamer-protein particles. It also relates to poloxamer-protein particles obtainable by this method, dispersion thereof, and their use in methods of encapsulation, in particular of microencapsulation.

Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof

A method of repairing tissue includes implanting into a patient a therapeutically effective amount of a pharmaceutical composition including microparticles including a biodegradable, biocompatible material having cells of interest or fragments thereof adhered to at least a portion of a surface; and at least one substance active on the cells or their environment upon implantation of the microparticles in a patient associated with the material wherein the substances is released in a controlled or extended manner.

Microparticles supporting cells and active substances

The invention relates to a composition comprising in an aqueous phase, particles having a diameter in the range of 20 to 500 nm, said particles containing:&#x2014;an oil phase;&#x2014;in said oil phase,&#x2014;an aqueous droplet, or&#x2014;a nanocapsule (NC) comprising:&#x2014;an aqueous core, and&#x2014;a polymeric shell or a shell composed of an amphiphilic substance; and&#x2014;a surfactant. This composition is particularly useful for encapsulating hydrophilic and/or lipophilic substances.

Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules

The present invention relates to a liquid lipid core/solid lipid shell capsule surface-functionalized with at least one compound containing at least one amino function, characterized in that the lipid core/lipid shell architecture is on the nanometric scale and in that said compound is covalently bonded to said solid lipid shell via a transacylation reaction. It also relates to a method for preparing such capsules.

Method for preparing functionalized lipid capsules

The invention relates to nanocapsules with a liquid lipidic core and a solid lipidic shell, the lipidic core being loaded with at least one water-soluble or water-dispersible ingredient, said ingredient being present in the form of a reverse micellar system.

Nanocapsules with a liquid lipid core charged with water-soluble or water-dispersible active agents

Provided is a method for preparing nanocapsules having a liquid lipid core and a solid shell and charged in their lipid core with at least one hydrophilic active agent involving combining microemulsions where the active agent remains in the hydrophilic phase of a first microemulsion and chill-hardening the mixture to obtain the nanocapsules charged with the hydrophilic active agent. The nanocapsules comprise the lipid core which is liquid at room temperature and the nanocapsules are encapsulated in a film which is solid at room temperature.

Method of preparing lipid nanoparticles

A process for preparing nanocapsules with a liquid lipid core and a solid lipid shell, charged with at least one active agent. The process contains at least the steps of formulating a microemulsion by phase inversion of an emulsion, totally or partially forming from at least one active agent a second composition different than the microemulsion, placing the microemulsion in contact with the second composition under conditions suitable for interaction of the active agent with the microemulsion, and chill-hardening the microemulsion that has interacted with the active agent, to obtain the nanocapsules.

Process for preparing lipid nanoparticles

The present invention relates to a method for preparing particles, notably particles encapsulating an active substance. It also relates to particles obtainable by this process, dispersion thereof, and their use as a vehicle for pharmaceutical, cosmetic, diagnostic, veterinary, phytosanitary active substances or processed foodstuff.

[object Object]

The invention concerns nanocapsules, in particular with an average size less than 50 nm, consisting of an essentially lipid core liquid or semiliquid at room temperature, coated with an essentially lipid film solid at room temperature having a thickness of 2-10 nm. The invention also concerns a method for preparing same which consists in producing a reverse phase of an aqueous emulsion brought about by several temperature raising and lowering cycles. Said lipid nanocapsules are particularly designed for producing a medicine.

Lipid nanocapsules, preparation process and use as medicine

The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of at least 90 weeks, a therapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used preferably contain 5-fluorouracile of the tumor, by intratissular injection. The radiotherapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.

Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma

The present invention provides microspheres intended to be administered by injection comprising a protein active ingredient and an agent coating the active ingredient intended to prolong its release, wherein they are free of any trace of organic solvent and they can be obtained according to a coating method involving bringing the active ingredient and the coating agent into contact, with stirring, in a supercritical fluid, said coating agent being soluble in this supercritical fluid.

Prolonged release microspheres for injectable administration

The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a thereapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used prefereably contain 5-fluorouracile of the tumor, by intratissular injection. The radiothereapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.

The invention relates to a filament comprising thermoluminescent particles that are evenly distributed in a polymer matrix, characterized in that the polymer matrix is a thermoplastic polymer having sufficient adhesion with respect to said thermoluminescent particles in order to ensure the cohesion of said filament and being such that the thermoluminescent response (signal) of the filament corresponds substantially to the dose of radiation absorbed and obtained after the filament is placed in contact with a physiological medium. The invention also relates to a method for thermoluminescence-based measurement of doses of beta radiation delivered by a transmitter on a target organ of a mammal, characterized in that a group of inventive filaments is introduced to the desired spot, whereby part of the length of said filaments remains outside the irradiated area, and in that the filaments are removed after irradiation and thermoluminescence is determined.

Polymer filaments used as a thermoluminescent dosimeter

Growing community of inventors

Angers, France

Jean-Pierre Benoit